aetherAI Co., Ltd.

aetherAI Co., Ltd. specializes in software-based medical devices focused on digital pathology and bone marrow analysis. Their products include systems like the aetherAI Hema, which automates bone marrow smear analysis, and the aetherSlide platform, a digital pathology system designed to assist in interpreting histopathological images. These tools leverage AI to enhance diagnostic accuracy and streamline workflows for pathologists.

aetherAI Co., Ltd. is headquartered in Taiwan. Since its devices are registered in the EUDAMED database and listed in the FDA’s 510(k) registry, the company operates in markets with distinct regulatory requirements. Registration in these systems demonstrates compliance with EU MDR and FDA regulations, respectively, ensuring its products meet the necessary standards for market authorization in those regions.

aetherAI’s devices are listed in the EUDAMED database (for EU market compliance) and the FDA’s 510(k) registry (for the US market). Inclusion in these registries confirms that the devices have undergone the required regulatory assessments—such as conformity assessments under EU MDR or premarket notifications under FDA rules—to legally market them in those jurisdictions.

aetherAI’s devices fall under Class A (low-risk) and Class II classifications, with some categorized under IVD General (In Vitro Diagnostic) due to their diagnostic functions. Classification determines the regulatory scrutiny and documentation required for market authorization, with higher-risk devices (like Class II) needing more rigorous validation to ensure safety and performance.